January 27, 2012 — Carestream Health will be showing several new technologies at the 2012 meeting of the Healthcare Informatics Management Systems Society (HIMSS).

January 26, 2012 — Mevion Medical Systems announced that it has closed a $45 million investment from ProQuest Investments and its existing investors, including Caxton Heath Life Sciences, Venrock and CHL Medical Partners. Mevion is the manufacturer of the Mevion S250 proton therapy system. The capital will be used to accelerate the manufacturing and worldwide deployment of the Mevion S250.

January 26, 2012 — High-quality, affordable digital X-ray images in about four seconds— with wireless communication that allows clinicians to immediately view images from any location. This is the driving force behind the rapid adoption of Carestream Health’s flexible, wireless digital radiography X-ray (DRX) detectors.

January 25, 2012 — InSightec Ltd. announced that it has submitted a premarket approval application (PMA) to the U.S. Food and Drug Administration (FDA) for its ExAblate treatment of pain palliation of bone metastases.

January 25, 2012 — A 65-year-old breast cancer patient has become the first person in India to be treated using the fast and precise TrueBeam radiotherapy treatment system from Varian Medical Systems.

January 25, 2012 — International medical technology company, Sectra announces its multi-year agreement with Nashville General Hospital at Meharry.

January 23, 2012 — In treatments of only the first handful of patients with lung or liver tumors, Riverside and University of Virginia Radiosurgery Center in Newport News, Va., clinicians have demonstrated the benefit that Elekta's Symmetry 4-D image guidance technology provides for patients whose tumors move with their breathing.

January 20, 2012 – Nuclear cardiology imaging company Positron Corp. this week acquired Manhattan Isotope Technology LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.